Last 44 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.76 | — | 5.66 | — | — | — | 4.33 | — | — | — | 12.50 | — | — | — | — | — | 7.31 | — | 5.65 | 1.36 | 8.26 |
| — | — | +30.8% | — | — | — | -65.4% | — | — | — | — | — | — | — | — | — | -11.6% | — | -79.6% | — | — | |
| P/S Ratio | 215.85 | — | — | 529.36 | 49.44 | 146.99 | 230.53 | 77.59 | — | 223.59 | 3.59 | 4.52 | 3.23 | 6.26 | 8.19 | 8.97 | 2.43 | 3.03 | 1.24 | 1.12 | 3.14 |
| — | — | — | +582.2% | — | -34.3% | +6317.7% | +1616.8% | — | +3470.5% | -56.1% | -49.6% | +32.8% | +106.9% | +560.9% | +698.7% | -22.3% | -38.3% | -76.9% | -88.1% | -45.0% | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | 460.27 | — | — | — | 2.72 | 2.63 | 2.86 | 1.74 | 2.95 | 2.17 | 2.74 | 16.67 |
| — | — | — | — | — | — | — | — | — | +16821.9% | — | — | — | -7.9% | +20.9% | +4.3% | -89.5% | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | 11.55 | — | — | — | — | — | — | — | 16.00 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | 7.31 | — | — | — | — | — | — | — | 1.59 | 1.63 | 16.85 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -98.0% | — | — | |
| EV / EBIT | — | — | 3.42 | — | — | — | 2.01 | — | — | — | 7.38 | — | — | — | — | — | 3.71 | — | 2.46 | 0.63 | 5.67 |
| — | — | +70.0% | — | — | — | -72.7% | — | — | — | — | — | — | — | — | — | -34.6% | — | -84.4% | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | — | — | 100.0% | 100.0% | -2731.2% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -98.5% | -238.8% | -213.6% | 96.4% | 97.4% | 98.7% | 98.1% | 100.0% |
| — | — | — | 0.0% | 0.0% | -2831.2% | 0.0% | 0.0% | 0.0% | +201.6% | +141.9% | +146.8% | +3.7% | -201.1% | -341.8% | -317.8% | -3.6% | -2.6% | -1.3% | -1.9% | 0.0% | |
| Operating Margin | -3099.9% | — | — | -33973.1% | -2316.7% | -4660.6% | -7319.1% | -1989.9% | 3521.9% | -4541.3% | 41.1% | -228.6% | -439.5% | -199.4% | -355.1% | -309.5% | -50.6% | -7.7% | 35.3% | 31.7% | 13.6% |
| — | — | — | -1607.3% | -165.8% | -2.6% | -17893.7% | -770.6% | +901.3% | -2177.1% | +111.6% | +26.2% | -768.9% | -2483.1% | -1106.1% | -1076.9% | -471.4% | +4.2% | +1435.3% | +148.9% | +120.6% | |
| Net Margin | -4658.6% | — | — | -50233.3% | -9775.7% | -7942.9% | 5330.9% | -1610.0% | 1350.9% | -6248.8% | 41.4% | -973.0% | -2149.3% | -137.4% | -216.9% | -364.8% | 35.1% | -38.1% | 21.9% | 84.6% | 40.9% |
| — | — | — | -3020.1% | -823.7% | -27.1% | +12786.0% | -65.5% | +162.9% | -4447.4% | +119.1% | -166.7% | -6225.4% | -260.6% | -1090.6% | -531.0% | -14.2% | +48.0% | -5.7% | +138.0% | +131.6% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | -3215.8% | — | — | — | -14.3% | -16.3% | -25.7% | 6.6% | -9.0% | 11.8% | 73.5% | 645.9% |
| — | — | — | — | — | — | — | — | — | -22366.0% | — | — | — | -58.2% | -237.4% | -135.0% | -99.0% | — | — | — | — | |
| ROA | -35.6% | -3.7% | 4.5% | -13.4% | -27.7% | -9.4% | 4.0% | -4.2% | -2.3% | -6.0% | 4.1% | -18.0% | -86.4% | -7.3% | -7.7% | -13.5% | 3.4% | -4.3% | 5.2% | 18.8% | 7.5% |
| — | +60.3% | +13.5% | -219.4% | -1101.5% | -56.5% | -3.2% | +76.7% | +97.3% | +17.9% | +153.3% | -33.8% | -2623.8% | -70.2% | -249.7% | -171.5% | -54.2% | +58.1% | +101.7% | +231.0% | +183.9% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -235.6% | -35.9% | -11.7% | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | 19.48 | — | — | — | 0.17 | 0.53 | 0.51 | 0.40 | 0.45 | 0.39 | 0.63 | 1.57 |
| — | — | — | — | — | — | — | — | — | +11114.3% | — | — | — | -61.3% | +36.3% | -19.7% | -74.2% | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | 1.07 | — | — | — | — | — | — | — | 2.44 | 3.08 | 8.02 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -92.9% | — | — | |
| Current Ratio | 8.65 | 8.38 | 7.48 | 7.65 | 8.65 | 10.67 | 13.33 | 12.34 | 9.43 | 10.70 | 4.78 | 3.03 | 1.33 | 4.51 | 4.18 | 5.22 | 5.91 | 6.73 | 5.11 | 3.31 | 2.00 |
| — | -21.5% | -43.9% | -38.0% | -8.2% | -0.3% | +179.0% | +307.2% | +608.8% | +137.5% | +14.3% | -41.9% | -77.5% | -33.0% | -18.2% | +57.5% | +195.5% | +324.0% | +167.5% | +71.8% | +7.7% | |
| Quick Ratio | 8.65 | 8.38 | 7.48 | 7.65 | 8.65 | 10.67 | 13.33 | 12.34 | 9.43 | 10.70 | 4.78 | 3.03 | 1.33 | 4.51 | 4.18 | 5.22 | 5.91 | 6.73 | 5.11 | 3.31 | 2.00 |
| — | -21.5% | -43.9% | -38.0% | -8.2% | -0.3% | +179.0% | +307.2% | +608.8% | +137.5% | +14.3% | -41.9% | -77.5% | -33.0% | -18.2% | +57.5% | +195.5% | +324.0% | +167.5% | +71.8% | +7.7% | |
| Interest Coverage | — | — | 19.51 | — | — | — | — | — | — | — | — | — | — | -10.26 | -24.78 | -22.75 | 7.95 | -9.24 | 13.03 | 41.70 | 18.41 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 44 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RNAC stock.
Cartesian Therapeutics, Inc.'s current P/E is -1.8x. The average P/E over the last 1 quarters is 5.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Cartesian Therapeutics, Inc.'s current operating margin is -3099.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Cartesian Therapeutics, Inc.'s business trajectory between earnings reports.